2024年11月，全球医药市场共签署了80项资产授权和合作协议，与10月持平。中国市场达成40项交易，较10月的15项大幅增长，包括17项出海交易、6项引进交易和17项国内交易。
本月中国市场最引人注目的出海交易是礼新医药授予默沙东肿瘤资产LM-299的全球权益，首付款5.88亿美元，总价值32.88亿美元。最大的引进交易由WY Biotech和HCW Biologics达成，首付款700万美元。最领先的国内交易是东阳光药与三生制药就前者的临床三期资产克立福替尼达成的合作协议，首付800万美元。
国际市场上，10月份共签署了40项资产授权和合作协议。最大的一笔交易是Arrowhead与Sarepta就多个资产达成的全球许可和合作协议，首付款5亿美元，总价值11.375亿美元。
In November, a total of 80 licensing and cooperation deals were signed globally, which ison par with October. Within China's biotech industry, 40 deals were sealed, reflecting a remarkable increase from 15 deals in October. These included 17 out-licensing deals, 6 in-licensing deals, and 17 domestic agreements.
The standout out-licensing deal of the month was a Cooperation, Investment, and Option agreement between LaNova and Merck & Co. for the oncology asset LM-299, valued at $3,288 million, included an upfront payment of $588 million. The top in-licensing deal involved HCW Biologics and WY Biotech for a pre-clinical stage asset, with an upfront payment of $7 million. Meanwhile, the leading domestic transaction was between HEC Pharma and 3SBio for the Phase III asset, clifutinib, featuring an $8 million upfront payment.
On the global stage, 40 licensing and cooperation deals were finalized. The largest of these was the agreement between Arrowhead Pharmaceuticals and Sarepta Therapeutics, covering multiple assets, reaching a total value of $11,375 million, with an upfront payment of $500 million.
2b. In-Licensing Deals
2c. Domestic Licensing Deals
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit www.yafocapital.com
Event Name:
